The primary purpose of this proposal is for the University of Arkansas for Medical Sciences to participate actively in cooperative clinical trials of the Southwest Oncology Group. The Southwest Oncology Group is a major multidisease, therapeutic research organization consisting of 30 full member institutions. The University of Arkansas for Medical Sciences has been a member of the Southwest Oncology Group for 30 years. A full complement of 22 physician investigators in a variety of scientific disciplines at the University of Arkansas for Medical Sciences is committed to participation in cancer chemotherapy, surgery, and radiotherapy clinical trials. The University of Arkansas for Medical Sciences has assumed a leadership role in the Group in the study of optimal management of elderly cancer patients. Dr. David Lipschitz is Chairman of the Standing Committee on Cancer Management in the Elderly for the Southwest Oncology Group. A large number of new cases of head and neck cancer seen at the University of Arkansas for Medical Sciences will be entered onto Southwest Oncology Group protocols or local pilot studies. Likewise, many new cases of melanoma referred to the surgical oncologists will be entered onto cooperative clinical trials. In addition, the University of Arkansas for Medical Sciences has 11 physicians who are active participants in the Southwest Oncology Group Cooperative Group Outreach Program protocols. An average of 52 patients a year have been registered on Cooperative Group Outreach Program protocols. With the establishment of the Arkansas Cancer Research Center at the University of Arkansas for Medical Sciences the referral of new cancer patients will be increased. Furthermore, the close association of investigations in multidisciplinary oncology clinics at the Cancer Center, will ensure high quality participation of the University of Arkansas for Medical Sciences in multimodal group protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037981-07
Application #
3558192
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1984-07-15
Project End
1992-12-31
Budget Start
1990-01-01
Budget End
1990-12-31
Support Year
7
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Arkansas for Medical Sciences
Department
Type
Schools of Medicine
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Ailawadhi, Sikander; Jacobus, Susanna; Sexton, Rachael et al. (2018) Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J 8:67
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527

Showing the most recent 10 out of 189 publications